These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32019759)

  • 1. SONAR: Do a New Design and Statistically Significant Results Translate to Reliability?
    Walsh M
    Clin J Am Soc Nephrol; 2020 Jun; 15(6):889-891. PubMed ID: 32019759
    [No Abstract]   [Full Text] [Related]  

  • 2. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
    Heerspink HJL; Andress DL; Bakris G; Brennan JJ; Correa-Rotter R; Dey J; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray J; Perkovic V; Tobe S; Wigderson M; Parving HH; de Zeeuw D
    Diabetes Obes Metab; 2018 Jun; 20(6):1369-1376. PubMed ID: 29405626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A
    Waijer SW; Gansevoort RT; Bakris GL; Correa-Rotter R; Hou FF; Kohan DE; Kitzman DW; Makino H; McMurray JJV; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
    Clin J Am Soc Nephrol; 2021 Dec; 16(12):1824-1832. PubMed ID: 34853062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
    Heerspink HJL; Xie D; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Perkovic V; Rossing P; Parving HH; de Zeeuw D;
    J Am Soc Nephrol; 2021 Nov; 32(11):2900-2911. PubMed ID: 34551995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
    Heerspink HJL; Parving HH; Andress DL; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Melnick JZ; Miller MG; Pergola PE; Perkovic V; Tobe S; Yi T; Wigderson M; de Zeeuw D;
    Lancet; 2019 May; 393(10184):1937-1947. PubMed ID: 30995972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.
    de Zeeuw D; Coll B; Andress D; Brennan JJ; Tang H; Houser M; Correa-Rotter R; Kohan D; Lambers Heerspink HJ; Makino H; Perkovic V; Pritchett Y; Remuzzi G; Tobe SW; Toto R; Viberti G; Parving HH
    J Am Soc Nephrol; 2014 May; 25(5):1083-93. PubMed ID: 24722445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrasentan: The Difficult Task of Integrating Endothelin A Receptor Antagonists into Current Treatment Paradigm for Diabetic Kidney Disease.
    Ortiz A; Fernandez-Fernandez B
    Clin J Am Soc Nephrol; 2021 Dec; 16(12):1775-1778. PubMed ID: 34853063
    [No Abstract]   [Full Text] [Related]  

  • 8. Atrasentan for the treatment of diabetic nephropathy.
    Egido J; Rojas-Rivera J; Mas S; Ruiz-Ortega M; Sanz AB; Gonzalez Parra E; Gomez-Guerrero C
    Expert Opin Investig Drugs; 2017 Jun; 26(6):741-750. PubMed ID: 28468519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.
    Schievink B; de Zeeuw D; Smink PA; Andress D; Brennan JJ; Coll B; Correa-Rotter R; Hou FF; Kohan D; Kitzman DW; Makino H; Parving HH; Perkovic V; Remuzzi G; Tobe S; Toto R; Hoekman J; Lambers Heerspink HJ
    Eur J Prev Cardiol; 2016 May; 23(7):758-68. PubMed ID: 26229089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.
    Kohan DE; Lambers Heerspink HJ; Coll B; Andress D; Brennan JJ; Kitzman DW; Correa-Rotter R; Makino H; Perkovic V; Hou FF; Remuzzi G; Tobe SW; Toto R; Parving HH; de Zeeuw D
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1568-74. PubMed ID: 26153128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.
    Smeijer JD; Kohan DE; Rossing P; Correa-Rotter R; Liew A; Tang SCW; de Zeeuw D; Gansevoort RT; Ju W; Lambers Heerspink HJ
    Cardiovasc Diabetol; 2023 Sep; 22(1):251. PubMed ID: 37716952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.
    Kohan DE; Pritchett Y; Molitch M; Wen S; Garimella T; Audhya P; Andress DL
    J Am Soc Nephrol; 2011 Apr; 22(4):763-72. PubMed ID: 21372210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
    Pena MJ; de Zeeuw D; Andress D; Brennan JJ; Correa-Rotter R; Coll B; Kohan DE; Makino H; Perkovic V; Remuzzi G; Tobe SW; Toto R; Parving HH; Sharma S; Corringham T; Sharma K; Heerspink HJL
    Diabetes Obes Metab; 2017 May; 19(5):749-753. PubMed ID: 28019071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
    Zhou Y; Chi J; Huang Y; Dong B; Lv W; Wang YG
    Diabet Med; 2021 Jan; 38(1):e14411. PubMed ID: 33000477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.
    Smeijer JD; Koomen J; Kohan DE; McMurray JJV; Bakris GL; Correa-Rotter R; Hou FF; Januzzi JL; Kitzman DW; Kolansky DM; Makino H; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
    JACC Heart Fail; 2022 Jul; 10(7):498-507. PubMed ID: 35772861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).
    Andress DL; Coll B; Pritchett Y; Brennan J; Molitch M; Kohan DE
    Life Sci; 2012 Oct; 91(13-14):739-42. PubMed ID: 22326504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline characteristics and enrichment results from the SONAR trial.
    Heerspink HJL; Andress DL; Bakris G; Brennan JJ; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray J; Perkovic V; Tobe S; Wigderson M; Yi T; Parving HH; de Zeeuw D
    Diabetes Obes Metab; 2018 Aug; 20(8):1829-1835. PubMed ID: 29604160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy.
    Boels MG; Avramut MC; Koudijs A; Dane MJ; Lee DH; van der Vlag J; Koster AJ; van Zonneveld AJ; van Faassen E; Gröne HJ; van den Berg BM; Rabelink TJ
    Diabetes; 2016 Aug; 65(8):2429-39. PubMed ID: 27207530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Webb DJ; Coll B; Heerspink HJL; Andress D; Pritchett Y; Brennan JJ; Houser M; Correa-Rotter R; Kohan D; Makino H; Perkovic V; Remuzzi G; Tobe SW; Toto R; Busch R; Pergola P; Parving HH; de Zeeuw D
    Drugs R D; 2017 Sep; 17(3):441-448. PubMed ID: 28831752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease.
    Smeijer JD; Koomen JV; Kohan DE; McMurray JJV; Bakris GL; Correa-Rotter R; Hou FF; Kitzman DW; Makino H; Mayer G; Nowicki M; Perkovic V; Rossing P; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
    Clin Pharmacol Ther; 2022 Nov; 112(5):1098-1107. PubMed ID: 35892316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.